Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer

Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer

Background: The inactivation of tumor-suppressor p53 plays an important role in second generation anti-androgens (SGAs) drug resistance and neuroendocrine differentiation in castration-resistant prostate cancer (CRPC). The reactivation of p53 by blocking the MDM2–p53 interaction represents an attrac...

Full description

Bibliographic Details
Main Authors: Meng Wu, Jingyi Cui, Huimin Hou, Ying Li, Shengjie Liu, Li Wan, Lili Zhang, Wei Huang, Gaoyuan Sun, Jingchao Liu, Pengfei Jin, Shunmin He, Ming Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Pharmacology
Subjects:
MDM2 inhibitor
enzalutamide resistance
combination therapy
castration-resistant prostate cancer
p53
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.871259/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.871259/full

Similar Items